Literature DB >> 19878373

Age-neutral guidelines for the primary prevention of cardiovascular disease.

William J Kostis1, John B Kostis.   

Abstract

Use of common guidelines for primary prevention of cardiovascular events based on 10-year risk results in undertreatment of younger individuals, especially women, since age and sex are major determinants of global risk. Women in their late 40s have a 10-year risk lower than the 10% threshold used for cholesterol-lowering treatment even in the presence of marked elevations of blood pressure or cholesterol. Removal of age from risk algorithms and use of lifetime global risk to treat individuals according to the degree of their modifiable risk factors rather than demographics has been proposed. Initiation of therapy at younger ages, aiming at "primordial" prevention of atherosclerotic disease rather than focusing on cardiovascular events, will result in saving more quality-adjusted life-years. Generic medications can be obtained at an affordable cost, and concerns about long-term safety and efficacy can be tested in a clinical trial of younger individuals at low 10-year risk but high lifetime risk. 2009 Wiley Periodical, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878373      PMCID: PMC8673238          DOI: 10.1111/j.1751-7176.2009.00162.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  17 in total

Review 1.  The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension: a Markov decision analysis.

Authors:  Peter R Jackson
Journal:  J Hypertens       Date:  2003-09       Impact factor: 4.844

2.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Authors:  James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Journal:  Am J Cardiol       Date:  2006-02-28       Impact factor: 2.778

3.  Biomedicine. Lowering LDL--not only how low, but how long?

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  Science       Date:  2006-03-24       Impact factor: 47.728

4.  Genetic risk prediction--are we there yet?

Authors:  Peter Kraft; David J Hunter
Journal:  N Engl J Med       Date:  2009-04-15       Impact factor: 91.245

Review 5.  Lipid lowering for primary prevention.

Authors:  Salim Yusuf; Eva Lonn; Jackie Bosch
Journal:  Lancet       Date:  2009-04-04       Impact factor: 79.321

6.  Personalized medicine in the era of genomics.

Authors:  Wylie Burke; Bruce M Psaty
Journal:  JAMA       Date:  2007-10-10       Impact factor: 56.272

7.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

8.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina
Journal:  Eur Heart J       Date:  2007-08-28       Impact factor: 29.983

9.  Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults.

Authors:  Amanda D Hyre; Paul Muntner; Andy Menke; Paolo Raggi; Jiang He
Journal:  Ann Epidemiol       Date:  2007-03-28       Impact factor: 3.797

10.  Disputation on the use of age in determining the need for treatment of hypercholesterolemia and hypertension.

Authors:  John B Kostis
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

View more
  1 in total

Review 1.  How low an LDL-C should we go with statin therapy?

Authors:  William J Kostis
Journal:  Curr Atheroscler Rep       Date:  2014-02       Impact factor: 5.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.